GQ1005

DRUG2 trials

Sponsors

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Conditions

HER2 Expressing or Mutated Advanced Malignant Solid TumorsHER2-positive Breast Cancer

Phase 1

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

GeneQuantum Healthcare (Suzhou) Co., Ltd.HER2 Expressing or Mutated Advanced Malignant Solid Tumors

Start: 2022-11-23End: 2025-07-30Target: 150Updated: 2023-12-04

Phase 3

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

RecruitingNCT07673029

GeneQuantum Healthcare (Suzhou) Co., Ltd.HER2-positive Breast Cancer

Start: 2025-01-10End: 2028-01-09Target: 228Updated: 2026-06-29

Related Papers

Abstract PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research2025-06-13

Abstract CT098: Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors

Cancer Research2024-04-051 citations